-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Minimed Group, Raises Price Target to $26

Benzinga·09/02/2026 13:10:46
Listen to the news
Mizuho analyst Anthony Petrone maintains Minimed Group (NASDAQ:MMED) with a Outperform and raises the price target from $21 to $26.